CN1291704C - Plaster design for post-operation incision - Google Patents
Plaster design for post-operation incision Download PDFInfo
- Publication number
- CN1291704C CN1291704C CN 200410025842 CN200410025842A CN1291704C CN 1291704 C CN1291704 C CN 1291704C CN 200410025842 CN200410025842 CN 200410025842 CN 200410025842 A CN200410025842 A CN 200410025842A CN 1291704 C CN1291704 C CN 1291704C
- Authority
- CN
- China
- Prior art keywords
- plaster
- wound
- healing
- postoperative
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000011505 plaster Substances 0.000 title claims abstract description 59
- 238000013461 design Methods 0.000 title abstract description 5
- 208000027418 Wounds and injury Diseases 0.000 claims abstract description 68
- 206010052428 Wound Diseases 0.000 claims abstract description 67
- 230000035876 healing Effects 0.000 claims abstract description 37
- 230000002980 postoperative effect Effects 0.000 claims abstract description 26
- 230000005389 magnetism Effects 0.000 claims abstract description 17
- 238000000034 method Methods 0.000 claims abstract description 17
- 239000002674 ointment Substances 0.000 claims description 50
- 230000029663 wound healing Effects 0.000 claims description 34
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 27
- 229910052725 zinc Inorganic materials 0.000 claims description 27
- 239000011701 zinc Substances 0.000 claims description 27
- 239000010949 copper Substances 0.000 claims description 14
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 13
- 229910052802 copper Inorganic materials 0.000 claims description 12
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 11
- 229920000742 Cotton Polymers 0.000 abstract description 14
- 239000004744 fabric Substances 0.000 abstract description 13
- 230000000202 analgesic effect Effects 0.000 abstract description 11
- 239000000853 adhesive Substances 0.000 abstract description 9
- 230000001070 adhesive effect Effects 0.000 abstract description 9
- 238000010521 absorption reaction Methods 0.000 abstract description 5
- 210000004877 mucosa Anatomy 0.000 abstract description 4
- 231100000957 no side effect Toxicity 0.000 abstract description 4
- 230000001737 promoting effect Effects 0.000 abstract description 4
- 231100000241 scar Toxicity 0.000 abstract description 4
- 208000032544 Cicatrix Diseases 0.000 abstract description 2
- 230000008901 benefit Effects 0.000 abstract description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 2
- 230000002349 favourable effect Effects 0.000 abstract 1
- 238000004321 preservation Methods 0.000 abstract 1
- 230000001681 protective effect Effects 0.000 abstract 1
- 230000037387 scars Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 36
- 238000002474 experimental method Methods 0.000 description 19
- 108010035532 Collagen Proteins 0.000 description 18
- 102000008186 Collagen Human genes 0.000 description 18
- 229920001436 collagen Polymers 0.000 description 18
- 208000002193 Pain Diseases 0.000 description 17
- 230000036407 pain Effects 0.000 description 17
- 210000004369 blood Anatomy 0.000 description 15
- 239000008280 blood Substances 0.000 description 15
- 210000000589 cicatrix Anatomy 0.000 description 15
- 239000011573 trace mineral Substances 0.000 description 11
- 235000013619 trace mineral Nutrition 0.000 description 11
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 10
- 208000015181 infectious disease Diseases 0.000 description 10
- 230000017531 blood circulation Effects 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 206010063560 Excessive granulation tissue Diseases 0.000 description 8
- 210000000416 exudates and transudate Anatomy 0.000 description 8
- 210000001126 granulation tissue Anatomy 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 206010061218 Inflammation Diseases 0.000 description 7
- 241000700159 Rattus Species 0.000 description 7
- 239000002390 adhesive tape Substances 0.000 description 7
- 230000004054 inflammatory process Effects 0.000 description 7
- 238000011084 recovery Methods 0.000 description 7
- 230000028327 secretion Effects 0.000 description 7
- 230000009471 action Effects 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 210000000981 epithelium Anatomy 0.000 description 6
- 239000000835 fiber Substances 0.000 description 6
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 5
- 239000004472 Lysine Substances 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 235000010323 ascorbic acid Nutrition 0.000 description 5
- 239000011668 ascorbic acid Substances 0.000 description 5
- 229960005070 ascorbic acid Drugs 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 210000003714 granulocyte Anatomy 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 230000003448 neutrophilic effect Effects 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 206010003011 Appendicitis Diseases 0.000 description 4
- 241000208340 Araliaceae Species 0.000 description 4
- 206010018852 Haematoma Diseases 0.000 description 4
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 4
- 235000003140 Panax quinquefolius Nutrition 0.000 description 4
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- 235000008434 ginseng Nutrition 0.000 description 4
- 238000002653 magnetic therapy Methods 0.000 description 4
- 230000035699 permeability Effects 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 210000002700 urine Anatomy 0.000 description 4
- 241001391944 Commicarpus scandens Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 230000004520 agglutination Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 230000004089 microcirculation Effects 0.000 description 3
- 206010033675 panniculitis Diseases 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 210000004304 subcutaneous tissue Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 229940091251 zinc supplement Drugs 0.000 description 3
- WHBMMWSBFZVSSR-UHFFFAOYSA-N 3-hydroxybutyric acid Chemical compound CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000009123 Fibrin Human genes 0.000 description 2
- 108010073385 Fibrin Proteins 0.000 description 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- 238000012313 Kruskal-Wallis test Methods 0.000 description 2
- XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 2
- 208000000114 Pain Threshold Diseases 0.000 description 2
- 108010050808 Procollagen Proteins 0.000 description 2
- 102000004079 Prolyl Hydroxylases Human genes 0.000 description 2
- 108010043005 Prolyl Hydroxylases Proteins 0.000 description 2
- 206010040880 Skin irritation Diseases 0.000 description 2
- 102000013275 Somatomedins Human genes 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 241000282894 Sus scrofa domesticus Species 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 210000000742 appendix Anatomy 0.000 description 2
- 210000002565 arteriole Anatomy 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000001772 blood platelet Anatomy 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 239000005515 coenzyme Substances 0.000 description 2
- 230000002016 colloidosmotic effect Effects 0.000 description 2
- 238000001804 debridement Methods 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 230000035617 depilation Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 229950003499 fibrin Drugs 0.000 description 2
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 2
- JFCQEDHGNNZCLN-UHFFFAOYSA-N glutaric acid Chemical compound OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 230000000640 hydroxylating effect Effects 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 210000000835 hypertrophic cicatrix Anatomy 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000000474 nursing effect Effects 0.000 description 2
- 230000037040 pain threshold Effects 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 208000009146 rhinoscleroma Diseases 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 230000036556 skin irritation Effects 0.000 description 2
- 231100000475 skin irritation Toxicity 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 210000000264 venule Anatomy 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 230000037314 wound repair Effects 0.000 description 2
- ZQBMUHABRSEAIK-UXBLZVDNSA-N 1-[4-[(e)-3-phenylprop-2-enyl]piperazin-1-yl]butan-1-one Chemical compound C1CN(C(=O)CCC)CCN1C\C=C\C1=CC=CC=C1 ZQBMUHABRSEAIK-UXBLZVDNSA-N 0.000 description 1
- 208000006770 Ascorbic Acid Deficiency Diseases 0.000 description 1
- 208000035404 Autolysis Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- LCWXJXMHJVIJFK-UHFFFAOYSA-N Hydroxylysine Natural products NCC(O)CC(N)CC(O)=O LCWXJXMHJVIJFK-UHFFFAOYSA-N 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 206010054923 Inflammation of wound Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010052904 Musculoskeletal stiffness Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 206010038419 Renal colic Diseases 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- 206010039580 Scar Diseases 0.000 description 1
- 206010040914 Skin reaction Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 206010043189 Telangiectasia Diseases 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 241000746998 Tragus Species 0.000 description 1
- 108010077465 Tropocollagen Proteins 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010047623 Vitamin C deficiency Diseases 0.000 description 1
- 206010053692 Wound complication Diseases 0.000 description 1
- ZOIORXHNWRGPMV-UHFFFAOYSA-N acetic acid;zinc Chemical compound [Zn].CC(O)=O.CC(O)=O ZOIORXHNWRGPMV-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 238000007486 appendectomy Methods 0.000 description 1
- 201000009361 ascariasis Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 210000000270 basal cell Anatomy 0.000 description 1
- 210000003445 biliary tract Anatomy 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000002975 chemoattractant Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 229910001882 dioxygen Inorganic materials 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 210000003725 endotheliocyte Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 230000003328 fibroblastic effect Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000002682 general surgery Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 230000003118 histopathologic effect Effects 0.000 description 1
- QJHBJHUKURJDLG-UHFFFAOYSA-N hydroxy-L-lysine Natural products NCCCCC(NO)C(O)=O QJHBJHUKURJDLG-UHFFFAOYSA-N 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- MRBDMNSDAVCSSF-UHFFFAOYSA-N phentolamine Chemical compound C1=CC(C)=CC=C1N(C=1C=C(O)C=CC=1)CC1=NCCN1 MRBDMNSDAVCSSF-UHFFFAOYSA-N 0.000 description 1
- 229960001999 phentolamine Drugs 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000035752 proliferative phase Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 208000010233 scurvy Diseases 0.000 description 1
- 230000028043 self proteolysis Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 238000009958 sewing Methods 0.000 description 1
- 230000035483 skin reaction Effects 0.000 description 1
- 231100000430 skin reaction Toxicity 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 210000005070 sphincter Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 208000026843 stiff neck Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000009056 telangiectasis Diseases 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 230000000283 vasomotion Effects 0.000 description 1
- 239000004246 zinc acetate Substances 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 229960001763 zinc sulfate Drugs 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
Images
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention relates to a design method of medical plasters especially plasters for postoperative incisions. A permanent magnetism sheet is fixed on a plaster to generate a magnetic field for promoting the healing of wounds. The present invention is characterized in that a hydro-entangled fabric is connected to the middle part of a non-dry adhesive base layer; a water absorption cotton core is coated in the hydro-entangled fabric; the permanent magnetism sheet is stuck on the water absorption cotton core; the outer surface of the plaster is provided with protective paper. The design method of plasters for postoperative incisions makes the plaster have the advantages of favorable moisture preservation performance, quick incision healing, durable analgesic effect, safety, no side effect and quick detumescence when the plaster used on operative incisions. The plaster is capable of preventing postoperative mucosa adhesion, and does not leave scars after the incisions are healed.
Description
Technical field: the present invention relates to a kind of medical application, the method for designing that particularly a kind of postoperative wound is applied ointment or plaster.
Background technology:
Magnetic therapy sheets has analgesic effect, because the analgesic effect immediately of magnetic therapy mainly is the irritability that reduces peripheral nerve.Magnetic therapy has bigger alleviation spasm effect, through clinical observation, can make stomach spasm, ascariasis of biliary tract under the action of a magnetic field, and patients' such as renal colic symptom is eased.This mainly is the result of magnetic field to sphincter, smooth muscle spasmolysis.In addition, when diseases such as treatment stiff neck, the obvious diastole of musculi colli before also can making, it is of flaccid muscles to treat the back, and pain is also alleviated thereupon.But the medicated magnetic plaster of patent application at present is mainly used in and relieves the pain and promote drug absorption, is not used in the postoperative wound healing.
The purpose of this invention is to provide the method for designing that a kind of postoperative wound is applied ointment or plaster, adopt this applying ointment or plaster on the operative incision, have good moisture preserving, wound healing is fast, analgesic effect lastingly, safely, have no side effect, subside a swelling fast, can prevent not long cicatrix after adhesion of postoperative mucosa and the healing.
Technical scheme of the present invention is: design the method for designing that a kind of postoperative wound is applied ointment or plaster, its adopts on applying ointment or plaster fixedly that the permanent magnetism sheet produces magnetic field to promote the healing of wound.
Middle part in adhesive sticker basic unit is connected with spun laced fabric, is wrapped in the suction cotton core in the spun laced fabric, posts the permanent magnetism sheet on the suction cotton core, and the outer surface of applying ointment or plaster has protection sheet.
On the described spun laced fabric trace element is arranged.
Described permanent magnetism sheet outer surface is coated with copper, ferrum, the zinc microelement that promotes wound healing, and wherein copper accounts for 0.5%-1%; Ferrum element accounts for 93%-95%; Zinc element accounts for 4%-6%.
Described trace element is a copper.
Described trace element is a ferrum element.
Described trace element is a zinc element.
Described spun laced fabric upper surface is covered with antiseized moisture film.
Spun laced fabric both sides in the described adhesive sticker basic unit are bonded with protection sheet respectively.
Trace element in the described dressing is that the fineness crossed through nanotechnology treatments is at 120 orders-200 purpose trace element.
The invention characteristics are: wound healing is the biological process of a complexity.The different mechanical factors acts on operation and the wound surface that different tissues causes and varies in size, and wound healing process is difference to some extent.Operative incision behind thorough debridement and suturing, Level of organization involutory good, wound healing is smooth, scar tissue seldom person is primary healing.Tissue defect is bigger, and slough is more or with infection, needing granulation tissue to fill up wound surface can healing person be secondary healing.The agglutination of operative incision roughly is divided into three phases, and they both had any different, and interknits juxtaposition again.Phase I is inflammatory reaction phase (being stage of preparation), exudate solidifies in wound, fibrin and fibronectin are bonding with wound, platelet, neutrophilic granulocyte, mononuclear cell, fibroblast and blood capillary enter in the wound in succession, justacrine plurality of enzymes and somatomedin start agglutination.Generally in 48 hours, the existing epithelium in the surface of whole wound covers.This phase lays a good foundation for healing, but wound tissue tension intensity is very low in initial 2-3 days.Phase III is a proliferative phase, and postoperative 4-5 days granulation tissue (fibroblast, blood capillary system and substrate) active proliferation collagen stroma occurs, and increases sharply in the wound, and tissue tension intensity raises rapidly, and the peak of general hyperplasia is 2 weeks approximately after surgery.Phase III is the period of maturation, postoperative about January hyperplasia and tissue tension growth rate slow down, cell number and vascularization reduce.After 60-80 days in the wound total collagen quantity reach normal value, and the synthetic of collagen still proceeded with decomposing, the cicatrix refigure, scanning electron microscope confirms that cicatrix fiber figure is in slow change in the several months.In wound healing process, microcirculatory perfusion well is a prerequisite with organizing oxygen supply, and macrophage, platelet and fibroblast play a crucial role.And the magnetic field that the permanent magnetism sheet produces has blood circulation promoting, the absorption that can quicken exudate is dissipated, removed the stimulation of inflammation swelling to nerve, observed by the microcirculation of many cases being sprained patient, the treatment metarteriole vein stasis of blood stagnates, slow blood flow, the part serious symptom has capillary break-up to go out clot, all case blood flow quickenings after the magnetic therapy, and the vein end stasis of blood stagnates and dissolves gradually, wherein most patients cure the back check and all recover normal, and the microcirculatory effect that has clear improvement is described.
Trace element effect in the dressing is as follows:
1, the synthetic and Cu of collagen
2+Relation: the tropocollagen molecules that three peptide chains are formed, its tensile strength of initial period be a little less than.As time passes, between three peptide chains or neighboring molecule form covalent bond, tensile strength just is increased.Though between the intramolecularly of collagen fiber and the molecule character of covalent bond also under study for action, some key internal reaction is determined, as the interconnection of lysine between two peptide bonds.Lysine changes aldehyde earlier into, and the aldehyde radical on two peptide chains reacts and links up then.Under the catalysis of lysyl amino oxidase lysine become-need Cu in the reaction of semialdehyde-a amine adipic acid
2+Be cofactor.The exhaustion of copper or the not enough formation and the crosslinked connection that will influence aldehyde.
2, the synthetic and Fe of collagen
2+Relation with ascorbic acid: also have characteristics during collagen is synthetic, be that proline or lysine are not that first hydroxyl turns to resynthesis collagen after hydroxyproline or the hydroxylysine, but proline or lysine participates in after the synthetic procollagen, makes proline hydroxylating on the peptide chain by the peptidyl-prolyl hydroxylase again.In the hydroxylating process, the oxygen atom in the hydroxyl is from airborne molecular oxygen.The peptidyl-prolyl hydroxylase is substrate and Fe except that needing a-copper 1,3-propanedicarboxylic acid
2+Outside cofactor, also need ascorbic acid as electron donor.So ferrum and ascorbic acid are the necessary materials of wound healing.The general otch that does not infect, postoperative 7d left and right sides collagen forms, and can make patient be engaged in general unlikely the splitting of movable otch, and can take out stitches and leave hospital this moment.But the formation of wound collagen and crosslinked sustainable several months or for many years, this period still needs constantly to replenish ascorbic acid.If lack ascorbic acid, vitamin C deficiency can appear in patient, and otch still has the possibility of splitting under external force.
3, the relation of wound healing and zinc: zinc is the coenzyme of many enzymes in the body or the composition of prothetic group, and extensive influence body internal protein, fat and sugar metabolism.Particularly zinc is the coenzyme composition of archaeal dna polymerase and RNA polymerase, with the division and the proteinic synthetic substantial connection that all has of cell.With closely-related proteoglycan of wound healing and collagen fiber, on chemical constituent, all belong to protide, so zinc also influences the synthetic of them.Moreover, zinc is more remarkable to the influence that the wound epithelium covers, and this influences cell division and growth from zinc, influences proteinic synthetic, and 20% zinc is present in the skin in the body, especially concentrates on epithelial tissue (zinc content is up to 120～250 μ g/g) and can obtain explaining.Many scholar's research affirm that body is in when hanging down the zinc state, and zinc supplement has facilitation to wound healing.And stress the time (as operation) discharge and increase along with urinary nitrogen, urine phosphorus, urine sulfur etc., urine zinc is discharged and is also increased.Because of zincode easily combines with some low-molecular-weight chemical compounds such as aminoacid, beta-hydroxybutyric acid etc. in the blood plasma, filtered and discharge by kidney, so when albumen was lost from urinate, zinc was also lost thereupon.Urine zinc is lost the degree that descends with blood plasma zinc and the length of persistent period with the character of wound and the order of severity and different.So operation back body more or less is in low zinc state for some time, as is replenished then and can be promoted the epithelium wound healing.If zinc supplement before the operation although postoperative still has blood zinc to reduce, can keep normal level.Come zinc supplement with zinc sulfate or zinc acetate clinically.Food aspect, animal skin zinc content are all very high, when as a supplement during the source of glycine, proline, also having obtained the zinc of volume with Corii Sus domestica or Ungula Sus domestica simultaneously.
The present invention has following effect in a word:
1, has good moisture preserving, be beneficial to wound healing.
2, good permeability can guarantee the eupnea of skin.
3, the exudation effect is strong, is beneficial to tissue repair.
4, analgesic effect lastingly, safely, have no side effect.
5, detumescence is fast, than common dressing fast about 3 days.
6, antiinflammatory can be avoided infection of incisional wound, be alleviated patient's burden.
7, can prevent the adhesion of postoperative mucosa.
8, can shorten healing time.
9, finished the cicatrix time of moulding again in advance in 5 months, and not long cicatrix after the healing.
10,1/3 time finished in advance can to make healing time.
11, subcutaneous nothing scleroma phenomenon, the tissue blood circulation is good.
12, sticking wound is removed when changing dressings the back destruction to new granulation tissue from.
13, can make the ulcer wound healing, alleviate patient's misery.
14, the wound after the healing, the sensation of depletion of YIN it rains sufferings has been removed patient's sequela from.
15, contained trace element is copper, ferrum, zinc in the dressing, and these trace element have facilitation to wound healing, is that wound healing is requisite.
16, the moisture film in the dressing keeps the wound surface moist environment, and the damaged tissues wound surface is created a moist environment, because the autolysis of moistening wound surface, its healing can be simplified debridement, promotes the cleaning of wound.Because the wound surface exudate is a ring of whole agglutination, exudate contains a great deal of to the indispensable somatomedin of wound healing process, and its kind and quantity play important regulating action to wound healing; Its function comprises stimulates fibroblast proliferation as macrophage, all many-sides such as chemical chemoattractant of neutrophilic granulocyte and smooth muscle cell.Moist environment helps the wound healing performance: (1) protection granulation granule; (2) the inflammation diffusion is disappeared; (3) wound pain alleviates; (4) exudate reduces; (5) fibrin film appears; (6) growth of wound surface microbial bacterial is suppressed, and pathogen disappears; (7) wound re-epithelialization ability improves.
One, accelerates healing speed, minimizing cicatrization.
Wound healing time, Dditch discovers: wound surface 10d healing person, the incidence rate of cicatrix is 0-6%, hinders back 10-14d healing, and incidence rate is 4%-19%, and after the 14-21d healing, sending out the back rate is 30%-35%, and mostly is hypertrophic cicatrix after hindering.Wound 21d is just healing later on, and incidence rate is 60%-80%.This shows healing time to the generation of growth property cicatrix be formed with confidential relation.Of the present invention applying ointment or plaster compared fast 18-20d to speed of wound healing than the wound of common dressing parcel, compare with biopsy wound healing rate, all healings of two week of wound back of applying ointment or plaster and covering of the present invention, and healing back cicatrix is slight, and common dressing covers wound, have only 63% healing, and the generation of hypertrophic cicatrix is arranged more.
Two, pain relieving, detumescence, antiinflammatory
The postoperative disorganization, circulatory disturbance, neural destruction exposes, and organizes transudate that the stimulation of otch is caused pain.Of the present invention apply ointment or plaster cover pain behind the wound and significantly be lighter than the patient that those fine mesh gauzes cover wounds, particularly postoperative anesthetic action and disappear after, in 72 hours the pain difference very obviously, (p (0.001).Of the present invention applying ointment or plaster can be loosened 50-100 μ arteriole and be improved the vasomotion of 20-30 μ arteriole, and the permeability that suppresses venule portion is hyperfunction, makes the blood exudate of the state of smouldering recover normal rapidly.Under effect of applying ointment or plaster of the present invention, blood can bring out a kind of Joule heat in body circulation time, impels telangiectasis, and blood flow is accelerated, so reach analgesic effect.And then suppress histamine, 5-hydroxy tryptamine, the slow stimulation that swashs chemical substances such as titanium to teleneuron.Eliminating postoperative edema is postoperative human body spontaneous recovery process, of the present invention apply ointment or plaster to have to stop ooze out and sorbefacient dual function, the hematoma area is littler by about 50% than common dressing after 3 days, regression time fast 60%; This is that blood flow rate has due to the optimum effect because of of the present invention applying ointment or plaster to microvascular permeability, colloid osmotic pressure.Of the present inventionly apply ointment or plaster better, bacterium property inflammation is had better curative effect too the aseptic inflammation curative effect.Because of leukocyte under the action of a magnetic field, phagocytic function obviously strengthens, neutrophilic granulocyte accounts for 70% of total white blood cells, neutrophilic granulocyte has to be engulfed and germ-resistant function, in body, play important defense reaction, the inflammation of wound healing is a feature with the quick gathering of neutrophilic granulocyte to the injury promptly in early days, and it mainly act as infection.
The analgesic test experimental technique
1,50 ♂ ♀ half and half of SD kind rat, body weight 167.7+16.4g is divided into 5 groups at random, and 3 the dosage groups of applying ointment or plaster of the present invention with the present invention's design are respectively 2000Gs, 1800Gs, 1500Gs; 30 rat backs cut off 4 * 1.5cm dorsal body setae, by the sterilization of operation specification handles, cut-3cm is long, and the degree of depth is the 3mm edge of a knife, sews up two pins, and what lose money in a business and invent applies ointment or plaster.Dolantin is as positive controls, and dosage is 50mg/kg, and 10 rat the north cut off 4 * 1.5cm dorsal body setae, by the sterilization of operation specification handles, cuts-3cm, and the degree of depth is the 3mm edge of a knife, sews up two pins, and common sterile gauze dressing is handled, experiment back 15min intraperitoneal administration; With the negative matched group of normal saline, dosage is 10ml/kg, and 30min filling stomach gives before the experiment.
2, the wound analgesic experiment is adopted in this experiment, measures the pain threshold of a rat.
Experimental result:
| Group | Number of animals (only) | Pain threshold (s) * ± s | |
| The dolantin group | 10 | 59.7±0.7 | |
| The normal saline group | 10 | 10.9±1.6 | |
| Permanent magnetism is of the present invention applies ointment or plaster | 2000GS | 10 | 48.8±3.1 |
| 1800GS | 10 | 45.2±4.2 | |
| 1500GS | 10 | 42.5±4.6 | |
Compare with the normal saline group
*P＜0.01.
Experiment conclusion: 3 the dosage groups of applying ointment or plaster of the present invention all have obvious analgesic activity under this experiment condition.
The microcirculation experiment
(1) method and result
50 of SD kind rats, body weight 167.1 ± 16.3g, ♂ ♀ half and half, random packet, the invention that loses money in a business be applied to rat ears root, normal saline and intramuscular injection phentolamine.The applying ointment or plaster of invention that lose money in a business is preceding measures the rat ears one blood capillary diameter of marked region with two observation by light microscope earlier, get under the same visual field average of the approaching substantially blood capillary diameter of several calibers, the metarteriole diameter of applying ointment or plaster as the invention that loses money in a business, each group is pasted the fast obedient 40min of healing and is observed the blood vessel diameter of measuring under the same visual field once more, gets the diameter of its average as the back blood vessel of applying ointment or plaster of the invention that loses money in a business.Add up the lose money in a business difference of blood capillary diameter before and after the applying ointment or plaster of invention of each treated animal, handle, the results are shown in following table with the paired t-test method statistic:
Of the present invention applying ointment or plaster to the cm that influences of rat ears blood capillary
The result shows that of the present invention applying ointment or plaster can obviously expand rat at the thin blood vessel of body tragus, and blood flow quickens, microcirculation improvement.
Experiment conclusion: the effect SD rat that applies ointment or plaster of the present invention can obviously be expanded blood capillary, and blood flow quickens, and improves circulation.
With the acute toxicity testing of applying ointment or plaster of the present invention:
1, totally 8 of Kunming mouses, male and female half and half, age in 8-10 week, body weight 18-22g.
2, preceding 8 mices of experiment are all taken off dorsal body setae, area 3 * 5cm
2
Cut homalographic when 3, testing and apply ointment or plaster, observe mice and have no adverse reaction in three weeks of mouse back.
The result: 8 mices there is no any untoward reaction (21 days).
The permanent magnetism repeatedly skin irritation test subject source of applying ointment or plaster of the present invention: Shanxi Zhongbang Pharmaceutical Technology Co., Ltd.'s experimental technique: 3 of rabbit, male and female are not limit, the heavy 2.5-3kg of female no conceptus.Test and cut off rabbit spinal column both sides 3 * 3cm dorsal body setae in preceding 24 hours.Depilation district, left side is coated with normal saline and does blank, and what right side region lost money in a business and invents applying ointment or plaster.Continuous once a day 14 times, observe the animal skin reaction.Experimental result: skin perusal and the equal zero difference of histopathologic examination, no abnormality seen are distinguished in 3 rabbit left sides or right depilation.
Experiment conclusion: according to " disinfection technology standard " skin irritation test evaluation criterion repeatedly, this is applied ointment or plaster to the skin nonirritant.
The present invention will be further described below in conjunction with the embodiment accompanying drawing.
Description of drawings:
Figure l is the example structure sketch map.
Fig. 2 is the embodiment cut-away view.
Among the figure: 1, adhesive sticker basic unit; 2, antiseized moisture film; 3, adhesive plaster; 4, permanent magnetism sheet; 5, suction cotton core; 6, carat hot paper; 7, spun laced fabric.
The specific embodiment:
Embodiment 1 as shown in Figure 1, mid portion in adhesive sticker basic unit 1 is connected with spun laced fabric 7, be wrapped in suction cotton core 5 in the spun laced fabric 7, post permanent magnetism sheet 4 on the suction cotton core 5, be stained with adhesive plaster 3 on the permanent magnetism sheet 4, the upper surface of spun laced fabric 7 is covered with antiseized moisture film 2, be bonded with a carat hot paper 6 respectively in spun laced fabric 7 both sides of adhesive sticker basic unit 1, cover the dressing surface and shield, be coated with trace element on the permanent magnetism sheet 4, wherein copper accounts for 0.8%; Ferrum element accounts for 94%; Zinc element accounts for 5.2%.Open a carat hot paper 6 during use, on wound, and be adjacent to fixing the dressing paste that is connected with permanent magnetism sheet 4 with the adhesive sticker basic unit 1 of spun laced fabric 7 both sides.Because copper, ferrum, the zinc element of plating emit in the wound under the effect of the magnetic line of force on the permanent magnetism sheet 4, add the effect of magnetic force, quickening cicatrizes a wound.This product amounts to seven kinds of specifications and sees the following form:
| Specification | The magnetic sheet number | Size | Explanation |
| 8×7 | 1 | cm | Adhesive tape size 8 * 7 |
| 12×10 | 2 | cm | Cotton core 12 * 5 adhesive tapes 18 * 10 |
| 18×10 | 3 | cm | Cotton core 18 * 5 adhesive tapes 22 * 10 |
| 22×10 | 4 | cm | Cotton core 22 * 5 adhesive tapes 28 * 10 |
| 28×10 | 5 | cm | Cotton core 28 * 5 adhesive tapes 34 * 10 |
| 35×10 | 6 | cm | Cotton core 35 * 5 adhesive tapes 41 * 10 |
| 42×10 | 7 | cm | Cotton core 42 * 5 adhesive tapes 48 * 10 |
| Remarks | Except that 8 * 7, all the other 6 kinds of specification illustrated dimension are meant cotton core length * tape width | ||
The clinical experiment result of embodiment 1 is as follows:
Patient's 140 examples at 3～31 years old age, will be divided into two groups with sick patient's random digit method of planting: experimental group, matched group.
The common dressing of matched group patient; After the experimental group patient implemented operation stitching, wound was disinfected by standard and is finished, and was about to dressing of the present invention and applied on otch by the wound size, and fix, until the doctor's advice nurse that takes out stitches provides special care to, and the patient who makes respective record and matched group makes contrast.Specifically be grouped as follows:
Experimental group: 80 examples, wherein gynecological's cesarean is routine with embodiment 3 dressing, appendicitis operation 16 example embodiment 4 dressing with dressing 30 examples, orthopaedics 14 example embodiment 1 dressing, the wound suture 20 of embodiment 2.
Matched group: 60 examples, wherein gynecological's cesarean 25 examples, orthopaedics 10 examples, wound suture 15 examples, appendicitis 10 examples of performing the operation.
Evaluation criterion
1. recovery from illness: wound surface does not have redness, no secretions, and the wound healing situation is good, local slight tenderness;
2. produce effects: wound surface is slightly red and swollen, no secretions, and wound healing is good, and there is slight tenderness the part;
3. effective: the local tenderness of wound surface, redness, wound healing is poor slightly, and a little secretions is arranged;
4. invalid: wound surface tenderness, redness, wound healing difference or infection is arranged;
Experiment is done statistical analysis by The Fourth Military Medical University's military medical equipment and meterological teaching and research room after finishing, and adopts SPSS10.0 statistics software kit.
The trial state record
| The operation branch | The example number | The set of applications healing state | The example number | Contrast back group healing state |
| Cesarean | 30 | 1. not too feel pain in postoperative 24-72 hour; 2. wound does not have 1 example infection; 3. healing is fast, and cicatrix is slight. | 25 | 1. sharp ache in the postoperative 24 hours, 4 example clothes tablet for alleviating pain, 1 example bucinnazine; 2. |
| Orthopaedics | 14 | 1. postoperative had mild pain in 72 hours, healing time is fast, and cicatrization is little; 2. healing is fast | 10 | 1. 72 hours pain of postoperative all needs analgesic control unbearably.2. cicatrization is obvious; 3.2 example infects. |
| Department of general surgery | 20 | 1. facial wound is after sewing up, and it is not obvious to use the back cicatrix of taking out stitches in 6-7 days.2. wound does not have the sense of tightening.3. healing is fast, and cicatrix is slight. | 15 | 1. cicatrization is obvious; 2. sense is tightened in the wound; 3. face scar easily causes burden at heart to the patient. |
| Appendectomy | 16 | 1. do not have cicatrization, 2. do not have 1 example and infect.3. healing is fast, and cicatrix is slight | 10 | 1.2 obvious 1 example of routine cicatrix infects; 2.24 sharp ache in hour. |
| Conclusion | 80 | Respond well | 60 | Generally |
1. efficacy analysis
Ranked data two samples relatively adopt non-ginseng Wilcoxon (Mann-Whitney Test) rank test.Ranked data are classified as follows table:
Table 1 patient uses and does not use dressing curative effect of the present invention relatively
| Curative effect | Use experimental group N (%) | Do not use matched group N (%) |
| Invalid effective produce effects recovery from illness | 2(2.50％) 23(28.75％) 38(47.50％) 17(21.25％) | 6(10.00％) 26(43.33％) 19(31.67％) 9(15.00％) |
| Add up to | 60 |
Assay:
P=0.012＜0.05, both can think: the patient uses and does not use the curative effect of applying ointment or plaster of the present invention that significant difference is arranged.The experimental group total effective rate is 97.50%;
To clinical effective rate analytic induction of the present invention be following some:
(1), have the effect of activating blood circulation to dissipate blood stasis, clinical trial result is (P＜0.01) obviously, curative effect obviously is better than matched group.
(2), can reduce inflammation to ooze out and quicken inflammation absorbs, isotopic labeling finds that the action of a magnetic field can be accelerated protein and shift.Regulate the colloid osmotic pressure gradient in the blood vessel, ooze out, promote wound healing thereby reduce.
(3), granulation tissue forms and epithelial cell takes place not to be obstructed, and shows degeneration or the paraplasm collagen of can selectively degrading under the wound condition of applying ointment or plaster of the present invention, and normal with newborn collagen is then had the growth of promotion effect.
(4), copper, ferrum, zinc element combines with dressing, complements each other, and has simultaneously to change the silt knot preferably and loose, the convergence granulation promoting suppresses the effect that cicatrization promotes wound repair.
(5), indication wide (P＞0.05), do not observed allergy and toxicity or local pain aggravation performance.
(6), when different age of operation patient uses of the present invention applying ointment or plaster, have a significant difference (P＜0.01) between its curative effect, compare with older patient, experimental result shows that between twenty and fifty patient's result of use is better;
Because this applies ointment or plaster and has no side effect, easy to use, use that the back wound healing is fast, subcutaneous tissue does not have scleroma, obtained the approval of doctor and patient during the clinic trial.
2. experimental group operation kind efficacy analysis
Whether the population distribution of inferring a plurality of independent samples of ranked data has difference, with non-ginseng sum of ranks Kruskal-Wallis Test check.Ranked data are classified as follows table:
Table 2 operation kind efficacy analysis
| Curative effect | Gynecological | Operation classification N (%) orthopaedics vermiform appendix | Outside general | |
| Invalid effective produce effects recovery from illness | 1(3.33％) 7(23.33％) 14(46.67％) 8(26.67％) | 1(7.14％) 5(35.71％) 6(42.86％) 2(14.29％) | 0(0.00％) 6(30.00％) 9(45.00％) 5(25.00％) | 0(0.00％) 5(31.25％) 9(56.25％) 2(12.50％) |
| Add up to | 30 | 14 | 20 | 16 |
Assay:
P=0.598＞0.05, both can think: different patient with operation use difference of applying ointment or plaster between the curative effect of the present invention not have the significance meaning, and its scope of application is more extensive;
Clinical: patient's 120 examples are observed by the court, at 22～58 years old age, will be divided into two groups with sick patient's random digit method of planting: experimental group, matched group.
Matched group patient routine is taken out stitches, common dressing; The experimental group patient spreads on of the present invention applying ointment or plaster on the otch on this basis, and postoperative uses first to paste, and takes out stitches and changes subsides, changes subsides behind the two weeks again, uses continuously 60 days, and 3 paste, and respectively each phase healing state is made record and gathers.Specifically be grouped as follows:
Experimental group: 60 examples, wherein gynecological's cesarean 20 examples, orthopaedics 14 examples, wound suture 10 examples, appendicitis 16 examples of performing the operation;
Matched group: 60 examples, wherein gynecological's cesarean 20 examples, orthopaedics 14 examples, wound suture 10 examples, appendicitis 16 examples of performing the operation;
Experiment situation record
First pastes operating position: postoperative is used first and is pasted, application process, and its pain relieving situation has only slight tolerability pain by patient main suit, other pain relieving method of stopping using simultaneously.Its analgesic effect is more remarkable; The affected part hematoma is eliminated fast, and the hematoma area is littler by about 50% than common dressing after 3 days, and regression time is fast 60%, prove of the present inventionly to apply ointment or plaster detumescence soon; Taking visible smooth, the soft scar of wound surface of the macroscopic view of applying ointment or plaster of the present invention when taking out stitches off is a fine rule, idol has a little blood crusts, and granulation tissue is good, and healing rate was faster than common dressing 18-20 days, and do not infect, healing rate has determined fulfiling ahead of schedule of repair in trauma.
Second pastes operating position: the back of taking out stitches is changed second and is pasted; wound surface is not seeing that infection handles the back through partly sterilised and use second subsides 10-15 days; it mainly is that the protection wound surface makes it avoid causing infection with the clothes friction; the reparation of what is more important otch basal cell is still being proceeded; the permeability that suppresses venule portion is hyperfunction; make the blood exudate under the state of smouldering recover normal rapidly; and then cause the reaction of connective tissues such as granulation tissue; make the secretion level of collagenase reach conventional value; impel the decomposition and the absorption of collagen fiber; so do not see cicatrization at 2-3 in week, can reach the standard of primary healing.
The 3rd pastes operating position: take 8～24 months time because of repair in trauma; 3 weeks of otch postoperative still need take good care of; at this moment continue to use meaning of applying ointment or plaster the protection otch of the present invention to be; impel to repair in advance and finished in 3 months; the 3rd pastes the doctor's advice patient sticked one month continuously; like this under the action of a magnetic field of applying ointment or plaster of the present invention; visible vessels endotheliocyte generation regression; this ischemia; anaerobic condition is that fibroblastic hypertrophy is suppressed; collagen fiber generate and to significantly reduce, and collagen fiber are and are arranged in parallel, and can reach and suppress synulotic purpose; and prevent the adhesion of subcutaneous tissue mucosa, and then avoided the sufferings reaction of it cloudy wound that rains.
Statistical analysis
Experiment is done statistical analysis by The Fourth Military Medical University's military medical equipment and meterological teaching and research room after finishing, and adopts SPSS10.0 statistics software kit.
1. evaluation criterion:
(1) recovery from illness: wound surface does not have redness, no secretions, and the wound healing situation is good, local slight tenderness;
(2) produce effects: wound surface is slightly red and swollen, no secretions, and wound healing is good, and there is slight tenderness the part;
(3) effective: the local tenderness of wound surface, redness, wound healing is poor slightly, and a little secretions is arranged;
(4) invalid: wound surface tenderness, redness, wound healing difference or infection is arranged;
2. use efficacy analysis
Ranked data two samples relatively adopt non-ginseng Wilcoxon (Mann-Whitney Test) rank test.Ranked data are classified as follows table:
Table 1 patient uses and does not use the curative effect of applying ointment or plaster of the present invention to compare
| Curative effect | Use experimental group N (%) | Do not use matched group N (%) |
| Invalid effective produce effects recovery from illness | 2(1.33％) 12(21.00％) 28(47.67％) 18(30.00％) | 6(10.00％) 25(41.67％) 20(33.33％) 9(15.00％) |
| Add up to | 60 | 60 |
P=0.001＜0.05, both can think: the patient uses and does not use the curative effect of applying ointment or plaster of the present invention that significant difference is arranged, and the experimental group total effective rate is 96.67%;
3. experimental group operation kind efficacy analysis
Whether the population distribution of inferring a plurality of independent samples of ranked data has difference, with non-ginseng sum of ranks Kruskal-Wallis Test check.Ranked data are classified as follows table:
Table 2 operation kind efficacy analysis
| Curative effect | Gynecological | Operation classification N (%) orthopaedics vermiform appendix | Outside general | |
| Invalid effective produce effects recovery from illness | 1(5.00％) 2(10.00％) 11(55.00％) 6(30.00％) | 0(0.00％) 3(21.43％) 5(35.71％) 6(42.86％) | 1(10.00％) 2(20.00％) 4(40.00％) 3(30.00％) | 0(0.00％) 5(31.25％) 8(50.00％) 3(18.75％) |
| Add up to | 20 | 14 | 10 | 16 |
P=0.588＞0.05, both can think: different patient with operation use difference of applying ointment or plaster between the curative effect of the present invention not have the significance meaning, illustrate that its scope of application is more extensive;
Conclusion
All do not find to infect through the wound surface of the nursing for treating of applying ointment or plaster of the present invention, and healing rate is faster than the otch of the deposited lid of common fine mesh gauze, new granulation tissue's generation and epithelial tissue obviously strengthen integral body and look like a plane, the incision softness, hematoma disappears substantially after 3 days, and regression time is fast.The most important thing is that all infection symptoms (redness is oozed out, pain, cicatrix) all obviously alleviate.We find being obstructed of the apply ointment or plaster formation that do not make granulation tissue and epithelial tissue of the present invention in the experiment, have intensive procollagen effect although show of the present invention applying ointment or plaster, and this effect is selectively.It can optionally degrade degeneration or abnormality proliferation collagen under the wound condition then has growth promoting function to normal with newborn collagen.Why Here it is can reach pain relieving simultaneously under the action of a magnetic field of applying ointment or plaster of the present invention, urge more, subside a swelling, suppress cicatrization, promotes one of reason of wound repair.
In whole clinical experiment, not observe the patient and allergy or toxicity occur, indication is wide, easy to use, does not also have the performance that the pain increased.Because healing rate is fast, the subcutaneous tissue phenomenon of not hardening, the patient comfort sense strengthens.The clinical trial personnel express very big interest to this product, and are ready to use this product in clinical, simultaneously consistently think that this is a kind of innovation, are a kind of contributions to improving quality of medical and nursing, and suggestion province Bureau of Drugs Supervision benefits the patient early by the evaluation of this product.
Claims (1)
1, a kind of postoperative wound method for designing of applying ointment or plaster, its adopts on applying ointment or plaster fixedly, and the permanent magnetism sheet produces magnetic field to promote the healing of wound, it is characterized in that: described permanent magnetism sheet outer surface is coated with copper, ferrum, the zinc microelement that promotes wound healing, and wherein copper accounts for 0.5%-1%; Ferrum element accounts for 93%-95%; Zinc element accounts for 4%-6%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410025842 CN1291704C (en) | 2004-02-15 | 2004-02-15 | Plaster design for post-operation incision |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410025842 CN1291704C (en) | 2004-02-15 | 2004-02-15 | Plaster design for post-operation incision |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1654032A CN1654032A (en) | 2005-08-17 |
| CN1291704C true CN1291704C (en) | 2006-12-27 |
Family
ID=34892267
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200410025842 Expired - Lifetime CN1291704C (en) | 2004-02-15 | 2004-02-15 | Plaster design for post-operation incision |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1291704C (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8705423B2 (en) | 2007-07-31 | 2014-04-22 | Johnson Controls Technology Company | Pairing wireless devices of a network using relative gain arrays |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102198287A (en) * | 2011-02-28 | 2011-09-28 | 北京上惠好生物技术有限公司 | Medical hydrogel and production technology |
-
2004
- 2004-02-15 CN CN 200410025842 patent/CN1291704C/en not_active Expired - Lifetime
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8705423B2 (en) | 2007-07-31 | 2014-04-22 | Johnson Controls Technology Company | Pairing wireless devices of a network using relative gain arrays |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1654032A (en) | 2005-08-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lee et al. | Extended negative pressure wound therapy-assisted dermatotraction for the closure of large open fasciotomy wounds in necrotizing fasciitis patients | |
| Hierner et al. | Skin grafting and wound healing—the “dermato-plastic team approach” | |
| US20100274177A1 (en) | Pulsed electromagnetic field and negative pressure therapy wound treatment method and system | |
| ES2526640T3 (en) | Compositions to break and inhibit the reconstitution of the wound biofilm | |
| US4778679A (en) | Method and composition for treatment of wounds | |
| CN114376993B (en) | Oxidase-carrying microneedle for promoting wound healing of diabetics and preparation method thereof | |
| Bello et al. | The role of graftskin (Apligraf) in difficult-to-heal venous leg ulcers | |
| Mizuguchi et al. | Successful treatment of necrotizing fasciitis after rectal surgery with the application of a negative-pressure wound therapy: a case study | |
| Cai et al. | Analysis of the Curative Effect and Influencing Factors of Collagen Sponge Combined with Autologous Skin Graft in the Treatment of Deep Burn Patients | |
| CN1649619A (en) | Method and composition for treating skin wounds with epidermal growth factor | |
| CN1291704C (en) | Plaster design for post-operation incision | |
| RU2423118C1 (en) | Method of treating trophic ulcers | |
| CN2696662Y (en) | Incision applicator for postoperation | |
| RU2577950C1 (en) | Method of stimulating healing dermal burns | |
| Niezgoda et al. | Wound treatment options | |
| Hayun et al. | Novel technologies in chronic wound care | |
| Khattabi et al. | Complete Healing and Short-term Treatment by Argania Honey Dressing in a Venous Leg Ulcer: A Case Report | |
| Alvarez et al. | A novel treatment for venous leg ulcers | |
| RU2463971C1 (en) | Complex method of treating trophic and sluggish wounds with application of immersion autodermoplasty and chitosan-based wound covering | |
| CN1213774C (en) | Technology for preparation of biological dressing material | |
| Devarajan | A Clinical Study to Evaluate the Effect of Aragwada Kshara Pratisarana and Jatyadi Gritha in Dushta Vrana WSR to Non Healing Ulcers | |
| RU2306939C1 (en) | Method for treating furunculosis cases | |
| RU2241480C2 (en) | Method for treating complications after endoprosthetics with hydrogels | |
| RU2178299C2 (en) | Method to treat gastroduodenal ulcers | |
| Tanigawa et al. | Use of trafermin to treat a skin ulcer after repair of a deep auricular laceration: a case report |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CX01 | Expiry of patent term |
Granted publication date: 20061227 |
|
| CX01 | Expiry of patent term |